NEW YORK and SYDNEY, November 10, 2020 (GLOBE NEWSWIRE) — Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”), an Australia-based diversified biopharmaceutical enterprise focused on the research, development, innovation and commercialization of therapies and products for treatment of global diseases, today announces the launch of a new product “Beilemei” in China. Beilemei is a probiotics health product.
Probiotics are live microorganisms known to provide health benefits when consumed. According to a paper published in Therapeutic Advances in Gastroenterology in January 2013, mechanisms of probiosis include manipulation of intestinal microbial communities, suppression of pathogens, immunomodulation, stimulation of epithelial cell proliferation and differentiation and fortification of the intestinal barrier.
Beilemei is formulated with 7 major active strains of probiotic cultures, including 3 strains of Bifidobacterium, 3 strains of Lactobacillus and a strain of Streptococcus. More than 30 billion live and active micro- organisms are contained in each dose. The retail price of this product is RMB200 (approximately US$30) and customers can place online orders at Beroni’s e-commerce sites.
“Beilemei is a healthy product.” commented Jacky Zhang, Chairman and CEO of Beroni Group. “We choose Fructooligosaccharide as sweetener, rather than sugar. This permits ingestion by individuals who follow special diets. The initial market response has been fantastic and we are expecting to sell approximately 10,000 boxes every month in the first year.”